Summary We previously reported the production of a panel of murine monoclonal antibodies which recognize glycoproteins abnormally expressed in human breast tumours. Using two of these antibodies, a double antibody radioimmunoassay was designed to quantify levels of these breast tumour marker glycoproteins in serum. Marker levels greater than 28 units were considered abnormal. Using this criterion, 63% and 75% of patients with breast cancer stages I and II, respectively, and 88% of those with metastatic disease were found to have elevated marker levels. Thirteen percent of patients with non-malignant breast disease also had elevated marker levels. Elevated marker levels were also detected in patients with non breast neoplasms. One hundred and eleven women with metastatic disease were followed. Eighty-two percent of those with progressive disease and 73% of those where disease regressed had 20% changes in marker levels. These changes in marker levels preceded by up to 6 months changes in disease state. From these results we conclude that this assay may be useful for monitoring the course of disease in breast cancer patients. al., 1984; Haynes et al., 1985) . Hilkens et al. (1986) followed a series of advanced breast cancer patients over a period of one to six months to correlate circulating antigen levels with the clinical course of the disease; the study examined a small sample size.
were the first to detect significant elevations of epithelial membrane antigens (EMA) in the sera of patients with advanced breast cancer using polyclonal antibodies produced against defatted human milk fat globule membrane. Burchell et al. (1984) later developed a quantitative double antibody serum assay by using monoclonal antibodies to human milk fat globule membrane antigens. Other investigations have also reported the presence of related breast tumour markers in the sera of breast cancer patients (Thompson et al., 1983; Papsidero et al., 1984; Haynes et al., 1985) . Hilkens et al. (1986) followed a series of advanced breast cancer patients over a period of one to six months to correlate circulating antigen levels with the clinical course of the disease; the study examined a small sample size.
We previously reported the production and characterization of a panel of monoclonal antibodies reactive with components of the EMA complex expressed at high levels in human breast tumours (Major et al., 1987a; Dion et al., 1987) . These antibodies react with two high molecular weight glycoproteins expressed in the majority of both primary and metastatic lesions. The panel of antibodies defines six epitopes present on molecules with apparent molecular weights of 300,000 and 280,000 daltons. Immunoblots of sera reveal that identical molecules are present in the circulation of patients with disseminated breast cancer (Major et al., 1987a) . We have used two of these antibodies to develop a double determinant radioimmunoassay for quantifying circulating marker levels. We report our results on the correlation of serum marker levels and clinical course in patients with metastatic breast cancer. In addition, serum marker levels were determined in patients with primary breast cancer and benign disease.
Materials and methods
Serum samples Blood samples were allowed to clot and then were centrifuged for 15 min at 800 g. The serum fraction was collected and 0.02% sodium azide was added to prevent Correspondence: A.S. Dion. Received 28 October 1987; and in revised form, 17 March 1988. bacterial growth. The serum was immediately frozen at -20 C. Normal sera were collected from apparently healthy women. Sera from patients with benign breast disease and primary breast cancer who had no clinical evidence of metastases were obtained prior to surgery. The clinical staging of patients with primary breast cancer was according to the system of the UICC (International Union Against Cancer). Serial blood samples for tumour marker, SMA-16 and CEA (CEA-EIA Roche, Nutley, New Jersey, USA) were collected at each clinic visit from patients with metastatic cancer. This group included 27 newly diagnosed cases initiating treatment; the other 84 patients had been treated previously and were being followed without therapy or were starting new courses of treatment. Samples were drawn at least two weeks after chemotherapy. Patients with an elevated bilirubin or a life expectancy of less than 6 months were not entered into the trial. The upper limit of normal for CEA was set at 5ngml-1. Sera from patients with widely disseminated malignancies other than breast cancer were also collected. When laboratory tests (X-rays, nuclear imaging, computed tomography) were positive, they were repeated at 2-4 months during treatment and thereafter when clinically appropriate. Stable disease, progression or regression were assessed according to the criteria previously used by Swenerton et al. (1979) for evaluating treatment response in patients with metastatic breast carcinoma. In the stable disease group all but 3 patients had a minimum follow-up of 6 months between evaluations without evidence of disease change. The exceptions were two patients who had a 3 month follow-up and one, a 5 month follow-up. The latter 3 patients were included when correlating marker value with disease. When estimating lead time, the time of observing progression or regression was compared to the time of rise or fall of breast tumour marker levels.
Serum samples were received with a patient information form indicating to which of the above groups the patient belonged. Samples were assigned numbers based on the order of accrual. Consecutive samples were assayed in batches. At the end of the study the clinical charts were used to verify the diagnosis and staging of all patients. In the case of patients with metastatic disease the information in patient information forms detailing the clinical course of their disease was verified in their hospital and clinical records and transferred to a flow sheet. At the end of the study the serum marker levels were entered on the flow sheet for compilation and statistical analysis. Br. J. Cancer (1988), 58, 362-367 363 Antibody production and radiolabelling The production and characterization of monoclonal antibodies MA6 and MA9 have been previously described (Major et al., 1987a; Dion et al., 1987 (Major et al., 1987a) ; a tumour membrane enriched preparation, MB5 (Major et al., 1987a) (Figure 1) . Serum from the normal female LS was used in the dilution of antigen standards because her serum gave the lowest signal (LS) in our control panel of normal sera.
Patient sera to be assayed were initially diluted 1:4 in buffer; all further dilutions were made in a solution of 3 parts dilution buffer and 1 part LS serum. All incubations were done at 37°C in a humidified chamber. Polyvinylchloride microtitration plates with round bottom wells (Fisher Scientific, Montreal, Canada) were coated with 4 pg per well of antibody MA9 in 50 p1 PBS and allowed to adsorb for 16 h. Unbound antibody was removed and 300 p1 blocking buffer (0.5% BSA, 0.02% sodium azide in PBS, pH 7.4) was added to the antibody coated wells for 30min. The plates were then washed twice with wash buffer (0.05 M phosphate, 0.5 M NaCl, 0.1% Tween 20 pH 8.0). Serum samples diluted as described above were added to blocked wells and incubated for 2h. Following two rinses with wash buffer, 0.1 pug labelled antibody MA6 was added and incubated for 2h. After 4 rinses with wash buffer, the wells were cut out and counted.
Statistical analysis All statistical analyses were performed on an IBM PC using the SPSS PC + statistical analysis program (SPSS Inc., Chicago, USA). The logarithm of the marker values was used for analysis. We used Pearson's linear correlation coefficient to identify any relationship between age and marker values in our normal control population. We took into account the possible interaction between groups and age when seeking to identify any relation between age and marker values in our patient population; for this purpose we used multiple hierarchical regression analysis (Draper & Smith, 1981) . We did one way analysis of variance followed by Student-Newman-Keuls multiple comparison of means (Sokal & Rohlf, 1981) to compare marker values in our control and patient groups. Kendall's tau B test was used as a measure of association between ordinal variables.
Results
Assay characteristics Linearity The standard curve generated with MB5 antigen is linear up to 90U. Standard curves were generated with quintuplicate values at each point on 6 different days; Figure  1 illustrates these results. The standard curves are consistent from day to day.
Stoichiometry To enable us to assay samples with marker levels outside the linear range of the standard curve, the stoichiometry of the assay was examined. Serum samples were diluted to give signals below 90 U. As an example, 800U of MB5 antigen was added to a 50pl serum sample. This antigen-spiked sample was diluted 1: 16 to yield a sample containing 50 U. The assay value of this latter sample (2723 cpm + 150) is comparable to that of the 50 U standard (2556 cpm + 91).
Reproducibility We studied within-day and between-day assay variations by assaying several samples in quintuplicate on 3 to 6 different days. Representative results for 4 serum samples are shown in Table I . The average of the coefficients of variation (Kennedy, 1984) is 5.6% for between-day variations and 5.1% for within-day variations. Within-day standard deviations of quintuplicate points never exceed 10% of the mean.
Specifcity The assay of undiluted serum yields a high background signal. This signal interference from serum Figure 2 , the curve is linear and passes through the origin.
Marker levels in normal females and patients with benign breast disease The mean marker value for all healthy women (Table II) was 13 U. The upper limit of normal was set at 28 U and includes 95% of normal women. Nineteen of our healthy females were followed over 24 to 36 months and had 4 to 6 serum samples drawn; marker value fluctuations were < 10%. Regression analysis showed no statistically significant association between age and marker levels (P=0.23). The sera of 4 pregnant and 2 lactating females were also assayed for antigen; no elevations in antigen were detected. Marker level fluctuations observed in 5 healthy premenopausal women during the menstrual cycle were within the limits of assay variation. Four of 29 patients with benign breast disease (as determined by clinical exam and mammography) showed elevations in marker (Figure 3) .
Marker levels in patients with malignancies other than breast cancer We tested the sera of 37 patients with various non-breast malignancies for circulating marker. All patients selected were in advanced stages of their disease with multiple visceral and/or bone metastases. As shown in Table III (Figure 3) . In those patients with Stage I disease, 63% had abnormal antigen levels, whereas 75% of women with Stage II disease were marker positive. Three of the 7 stage III patients had elevated levels.
We measured breast tumour marker and CEA serum levels in 39 consecutive patients with metastatic breast cancer. These results are summarized in Table IV . Thirty eight of these patients (97%) showed elevated breast tumour marker levels, but only 46% of the patients had elevated CEA values. CEA monitoring was omitted in subsequent patients.
In 111 patients with metastatic disease, 88% had elevated marker levels. These data are summarized in Figure 3 . Patients with metastatic disease had a mean level of 188U, well above the mean of any other stage. Circulating marker levels in patients with bone lesions are higher than in patients with visceral metastases. Marker levels are highest in patients with both bone and visceral disease. There is, however, significant overlap in marker levels between these groups. The results are summarized in Table V. The mean age of subjects in our groups was different (Table II) thus we needed to rule out any significant effect of age on marker levels. We first established that there was no significant relation between age of patients and groups (P=0.24). Regression analysis which took into account the groups allowed us to establish that there was no significant relation between age and marker levels (age effect: P=0.27; group effect: P<0.0001). The groups were then compared for mean marker levels using one way analysis of variance. The Student-Neuman-Keuls multiple comparison procedure was applied following one way analysis of variance. This revealed significant differences between the groups (P<0.0001). The multiple comparison procedure results are summarized in Table VI . Smoking or non-smoking healthy volunteers and those with benign breast disease did not differ amongst themselves but were different from patients Table  VII leaving a total of 109 patients for this analysis). This showed an optimal association when a 20% increase or decrease in marker values was the criterion selected (tau = 0.78). These results are summarized in Table VII . Amongst the 62 patients with disease progression, 51 (82%) had increases of >20% in serum marker levels; none had decreases of 20% or more. Thirty patients experienced a regression of their disease; in 22 (73%) there was a larger than 20% decrease in marker levels; no patients showed increases of 20% or more. Four patients with stable disease had a 20% increase in marker level and 2 patients showed a 20% decrease in marker; the other 11 had variations of less than 20%. Overall these data indicate that changes in marker level of 20% are quite specific.
The 6 false positives (the 4 patients with stable disease who show a 20% increase in marker level and the 2 patients with stable disease who show a 20% decrease in marker level) markedly affect the sensitivity of the assay. Five of these false positives had their change in marker value early (Bast et al., 1983; Del Villano et al., 1983; Klug et al., 1984; Sekine et al., 1985) . In breast cancer, the marker that has been most extensively evaluated is CEA. This marker, however, lacks sufficient sensitivity, and variations in serum levels appear to correlate poorly with the course of disease (Chu et al., 1973; Borthwick et al., 1976; Haagensen et al., 1978; De Jong-Bakker et al., 1981) . Elevated levels of epithelial membrane antigen (EMA) were first detected in serum of patients with breast cancer using polyclonal antibodies (Ceriani et al., 1982) . More recently monoclonal antibodies reactive with specific components of the EMA complex have been used to detect these antigens in the sera of patients with breast cancer (Thompson et al., 1983; Burchell et al., 1984; Papsidero et al., 1984; Haynes et al., 1985; Hilkens et al., 1986; Major et al., 1987a) .
We designed a double antibody radioimmunoassay using two monoclonal antibodies which both react with two specific components of the EMA complex. This combination of antibodies was selected for optimal specificity and sensitivity and the assay was designed to quantify marker levels.
The assay reported here is reproducible, linear from 0 to 90 U and stoichiometric beyond the linear range of the standard curve. Decreasing the serum protein content of samples by diluting in protein-free buffers leads to non-linear relations between marker level and assay signal; we determined that 1:4 dilutions of serum were optimal for reducing background and maintaining assay sensitivity (data not shown). Initially, all samples were diluted 1:4 in buffer and further dilutions were done in 1:4 dilutions of a reference serum (LS) to maintain the stoichiometry of the assay. This represents a technical improvement over other assays that have used end point dilution (Haynes et al., 1985) or log-linear standard curves (Hilkens et al., 1986) The antigen recognized by our antibodies is detectable by histochemistry in low levels in secretory epithelia other than breast (Major et al., 1987a) . We measured marker levels in patients with malignancies originating in these tissues and found only small elevations in cases of widely metastatic disease. Use of the marker would appear to be limited to patients with metastatic breast cancer.
There are several possible explanations for failing to detect elevated levels of marker in patients with primary (or metastatic) disease. The antibodies selected react with more than 90% of primary tumours. However, our immunoelectron microscopy studies (Major et al., 1987b) show that in vivo primarily breast tumours may contain large amounts of antigen in the cytoplasmic compartment and no detectable antigen at the cell surface. Such tumours may not shed antigen into the circulation. In addition, other investigators have documented the presence of EMA components in circulating immune complexes (Salinas et al., 1987) ; antigen bound in such complexes might not be detectable.
The initial evaluation of our assay shows a good correlation between changes in marker level and changes in the clinical status of patients with metastatic disease (Table   VII) (Major et al., 1987a) . A patient with a tumour containing predominantly non marker secreting cells will show a slower rise in marker level than a patient with a tumour containing mostly marker positive cells. This may explain the few cases where long lag-times for rises in marker levels were observed after clinical documentation of a change in disease state. Nevertheless our pilot study would appear to warrant evaluating usefulness of this assay in clinical practice for monitoring patients with metastatic disease.
